Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
URGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.42 - $21.71
Previous CloseN/A
Volume157.75K
Average Volume (3M)1.25M
Market Cap
$788.80M
Enterprise Value$623.47M
Total Cash (Recent Filing)$156.95M
Total Debt (Recent Filing)$125.92M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 17, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding46,264,133
10 Day Avg. Volume1,240,775
30 Day Avg. Volume1,245,779
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue6.62
Enterprise Value/Gross Profit7.47
Enterprise Value/Ebitda-5.30
Forecast
1Y Price Target
$36.83Price Target Upside118.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DataZUSDURI long-term clinical data appear compelling with a 78% complete response for patients at three months, and 79% of those patients remained event-free 12 months later.
Market PotentialZUSDURI could reach blockbuster status in the 2030 time frame given the much larger size of the NMIBC target market and the fact that ZUSDURI is currently the only pharmacotherapy approved to treat recurrent LG-IR-NMIBC.
Product LaunchThe Zusduri launch is progressing well, with the company pleased with the early progress and site activation going well.
Bears Say
Financial PerformanceRevenue and earnings miss moderately—lowering price target based on revised sales ramp trajectory.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $21.71 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $788.80M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 17, 2025 which is in 40 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.865 by -$0.185.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.66.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,264,133 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.865. Following the earnings report the stock price went down -7.096%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
Urogen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.83 (118.71% Upside)
$36.83 (118.71% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $176.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.25%
12-Months-Change
Fundamentals
Return on Equity
-452.20%
Trailing 12-Months
Asset Growth
-25.95%
Trailing 12-Months
Company Description
Urogen Pharma
Urogen Pharma Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases. The company specializes in the research and development of products designed to treat conditions such as bladder cancer and other urological disorders, leveraging its proprietary technology platforms to create targeted therapies. Urogen's core products include its lead investigational therapies, which aim to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions.
URGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including FDA approval of ZUSDURI and strong revenue growth for JELMYTO. However, these were balanced by challenges such as reimbursement issues for ZUSDURI and increased operating expenses, resulting in a larger net loss.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$36.83
▲(118.71% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.01% Insiders
2.33% Mutual Funds
49.80% Other Institutional Investors
40.66% Public Companies and Individual Investors